Unmet needs in high-risk MDS and future therapeutic strategies

In this video, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the challenge of treating patients with high-risk myelodysplastic syndromes (HR-MDS) and future therapeutic strategies being investigated. Dr Daver first highlights the area of unmet need in this disease, and the need to improve treatment options for patients. Following this, Dr Daver highlights some of the promising agents being evaluated for the treatment of HR-MDS, including venetoclax, magrolimab and sabatolimab, and the promise of combination therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.